The Synergistic Antitumor Activity of Chidamide in Combination with Bortezomib on Gastric Cancer

• Published in: OncoTargets and therapy Vol. 13; pp. 3823 - 3837
• Main Authors: Zhang, Wanjun, Niu, Junwei, Ma, Yongcheng, Yang, Xiawan, Cao, Huixia, Guo, Honggang, Bao, Fengchang, Haw, Ahmed, Chen, Yuqing, Sun, Kai
• Format: Journal Article
• Language: English
• Published: New Zealand Dove 01.01.2020; Dove Medical Press
• Subjects: bortezomib; chidamide; combination drug therapy; gastric cancer; Original Research; chidamide; gastric cancer; bortezomib; combination drug therapy
• ISSN: 1178-6930; 1178-6930
• DOI: 10.2147/OTT.S240721

The aim of this study was to investigate the antitumor effect of chidamide in combination with bortezomib on gastric cancer cell lines. First, the sensitivity and IC values of chidamide and bortezomib in several gastric cancer cell lines (MGC-803, BGC-823, SGC-7901, and MKN45) were measured using the CCK-8 assay. Then, the relatively insensitive gastric cancer cell lines (MGC-803 and BGC-823) were treated with low concentrations of chidamide alone, bortezomib alone, or chidamide and bortezomib combination to detect the effects on cell proliferation, apoptosis, migration, and invasion. Finally, the inhibitory effect of the combined chidamide and bortezomib treatment on MGC-803 cells was verified in vivo through tumor formation experiments in nude mice. Compared with low-dose chidamide or bortezomib alone, the low-dose drug combination significantly inhibited the proliferation, migration, and invasion of MGC-803 and BGC-823 cells and induced apoptosis of the cells. The effects of the low-dose chidamide and bortezomib combination reduced the growth on gastric cancer in vivo were investigated by using a subcutaneous tumor mouse model. Our results suggest that the combination of chidamide and bortezomib can significantly reduce the proliferation, invasion, and migration of MGC-803 and BGC-823 cells, providing a framework for the clinical evaluation of combined therapies for gastric cancers.